Dieter C. Gruenert, PhD, (bottom left) is a professor of otolaryngology—head and neck surgery at the University of California, San Francisco (UCSF) and pediatrics at the University of Vermont (UVM). He has a PhD in biophysics from the University of California at Berkeley and was a postdoctoral fellow in carcinogenesis at L’Institut Suisse de Recherche Expérimentale sur le Cancer in Lausanne. He was co- director of the Gene Therapy Core Center at UCSF, director of the Division of Human Molecular Genetics at  UVM, and head of the Stem Cell Research Program at California Pacific Medical Center. His research focuses on development of gene editing and cell-based therapies for inherited diseases and cancer. He has developed novel diagnostic and oligonucleotide-based therapeutic strategies to ameliorate disease pathology.

Scientists develop algorithm to uncover genomic insertions and deletions involved in autism, OCD.

New gene-editing technique allows scientists to more rapidly study the role of mutations in tumor development.

The license enables SAGE Labs to use the CRISPR/Cas9 system to engineer cell and animal models for their clients as well as distribute validated CRISPR reagents.

Support for researchers performing mutation detection and genome editing.

The Broad Institute announced April 15 that the United States Patent and Trademark Office has issued the first patent for an engineered CRISPR-Cas9 system that is enabling scientists to modify genes and better understand the biology of living cells and organisms. The institute applied for the patent in concert with the January 3, 2013 publication in Science (Cong, et al.) that described the use of the CRISPR enzyme, Cas9, for genome editing.

Work reveals how a genome-editing tool works to correct errors in the genetic code.

Berkeley Researchers Uncover the Key to Self-Awareness in Genome Editor.